National Trends in Diabetes Medication Use in the United States: 2008 to 2015
- PMID: 30572757
- DOI: 10.1177/0897190018815048
National Trends in Diabetes Medication Use in the United States: 2008 to 2015
Abstract
Background: Data on trends of diabetes medications use are sparse, outdated, and limited to prescription data. We determined trends in diabetes medication use among US individuals with diabetes during 2008-2015.
Methods: We used 2008-2015 Medical Expenditure Panel Survey to examine diabetes medication utilization among individuals aged ≥18 years with diabetes. Prescription medications were classified based on therapeutic class and subclass using Multum Lexicon database.
Results: From 2008 to 2015, use of any diabetes medication (81.4% vs. 87%), metformin (47.8% vs. 59.0%), and insulin (23.0% vs. 31.0%) increased, whereas, use of sulfonylurea (36.0% vs. 29.0%) and thiazolidinedione (21% vs. 9.0%) declined. A linear increase was observed in the uptake of dipeptidyl peptidase-4 (DPP-4) inhibitors from 6.2% in 2008 to 12.4% in 2015; glucagon-like peptide-1 (GLP-1) receptor agonists from 2.5% in 2008 to 4.4% in 2015 and sodium glucose transporter-2 (SGLT2) inhibitors from 0.8% in 2014 (the first SGLT2 inhibitors approval year) to 4.4% in 2015. Monotherapy use increased from 50.6% to 56.4% during 2008-2015, while triple therapy use declined.
Conclusions: Metformin, insulin and sulfonylureas remained the top-three prescribed classes of diabetes medications. Increased use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors was offset by decline in TZDs use.
Keywords: Medical Expenditure Panel Survey; diabetes; insulin; metformin; trends.
Similar articles
-
Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019.Diabetes Obes Metab. 2021 Aug;23(8):1843-1850. doi: 10.1111/dom.14408. Epub 2021 May 6. Diabetes Obes Metab. 2021. PMID: 33881795
-
Trends in add-on medications following metformin monotherapy for type 2 diabetes.J Manag Care Spec Pharm. 2022 Nov;28(11):1253-1259. doi: 10.18553/jmcp.2022.28.11.1253. J Manag Care Spec Pharm. 2022. PMID: 36282929 Free PMC article.
-
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.Cardiovasc Diabetol. 2020 Jul 6;19(1):107. doi: 10.1186/s12933-020-01078-5. Cardiovasc Diabetol. 2020. PMID: 32631337 Free PMC article.
-
Complementing insulin therapy to achieve glycemic control.Adv Ther. 2013 Jun;30(6):557-76. doi: 10.1007/s12325-013-0039-y. Adv Ther. 2013. PMID: 23797471 Review.
-
Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.Curr Med Res Opin. 2016 May;32(5):807-16. doi: 10.1185/03007995.2015.1135110. Epub 2016 Feb 29. Curr Med Res Opin. 2016. PMID: 26700585 Review.
Cited by
-
Improving Adherence and Reducing Health Care Costs Through Blister-Packaging: An Economic Model for a Commercially Insured Health Plan.Clinicoecon Outcomes Res. 2024 Oct 3;16:733-745. doi: 10.2147/CEOR.S480890. eCollection 2024. Clinicoecon Outcomes Res. 2024. PMID: 39376478 Free PMC article.
-
Persistence to Basal Insulin: Association With Health Outcomes in a Population With Type 2 Diabetes.Clin Diabetes. 2024 Spring;42(2):257-265. doi: 10.2337/cd23-0016. Epub 2023 Dec 19. Clin Diabetes. 2024. PMID: 38694243
-
Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage Receiving Sulfonylureas: A Propensity-Adjusted Analysis.World Neurosurg. 2023 Aug;176:e400-e407. doi: 10.1016/j.wneu.2023.05.073. Epub 2023 May 24. World Neurosurg. 2023. PMID: 37236313 Free PMC article.
-
Comparison of decision tree with common machine learning models for prediction of biguanide and sulfonylurea poisoning in the United States: an analysis of the National Poison Data System.BMC Med Inform Decis Mak. 2023 Apr 6;23(1):60. doi: 10.1186/s12911-022-02095-y. BMC Med Inform Decis Mak. 2023. PMID: 37024869 Free PMC article.
-
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.Am J Cardiovasc Drugs. 2023 May;23(3):277-286. doi: 10.1007/s40256-023-00572-x. Epub 2023 Feb 15. Am J Cardiovasc Drugs. 2023. PMID: 36790596 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
